S2015 VC Joins Syndicate Investment in Synex Medical: Pioneering Non-Invasive Glucose Monitoring

S2015 VC is proud to announce its participation in a syndicate investment in Synex Medical, a groundbreaking Health Tech company revolutionizing glucose monitoring in the USA diabetes market. Led by founder Ben Nashman, Synex's innovative approach to continuous glucose monitoring (CGM) promises to provide more accurate data and analytical tools through non-invasive technology.

Synex Medical is dedicated to providing users with accurate data about how their bodies are functioning so they can be proactive about their health. Using magnetic resonance, the same underlying principle used in Magnetic Resonance Imaging (MRI), the company has developed novel techniques that allow users to measure critical metabolites like glucose, lactate, and ketones in real-time, with the goal of providing consumers a compact non-invasive device. Founded in 2017, the company is headquartered in Toronto and backed by Accomplice and Radical Ventures.

Founder's Vision and Achievements: Ben Nashman's journey with Synex began during his high school years, where his innovative approach to diabetes solutions earned him recognition, including winning the 2017 NBTC Health Tech Competition and being named a Thiel Fellow. His dedication to developing novel NMR techniques has led to the creation of Synex's groundbreaking device, poised to make a transformative impact in the healthcare industry.

Market Opportunity and Impact: With diabetes affecting approximately 11.6% of the US population and healthcare costs associated with diabetes management reaching staggering figures, Synex's technology presents a game-changing solution. Priced at a fraction of the cost of traditional CGMs, Synex's device offers not only affordability but also versatility, with the capability to measure multiple metabolites beyond glucose. This positions Synex to address a significant market opportunity while providing substantial cost savings and improved quality of life for diabetic patients.

“What Synex has done is the biggest breakthrough in non-invasive health monitoring that I’ve seen in recent years. Showing that a portable magnetic resonance system can directly measure glucose is groundbreaking, and what many thought to be impossible. Their data is compelling, and highlights a path to a world-changing product with the potential to measure important metabolites in vivo.”

Dr. Matt Rosen, Director of Low-Field MRI at Harvard and Mass General Hospital

S2015 VC's participation in the syndicate investment underscores its commitment to supporting groundbreaking innovations with the potential for profound impact. Synex's pioneering technology aligns with S2015 VC's investment philosophy, which prioritizes disruptive solutions that address critical market needs and drive positive change.